What is the best treatment for a male patient with a urinary tract infection (UTI) and acute kidney injury (AKI)?

Treatment of UTI in Males with Acute Kidney Injury

For a male patient with UTI and AKI, initiate empiric broad-spectrum IV antibiotics immediately after obtaining cultures, with dose adjustments for renal function, while simultaneously addressing the underlying cause of AKI and avoiding nephrotoxic agents. 1, 2

Immediate Management Priorities

Diagnostic Workup

• Obtain blood and urine cultures before starting antibiotics to guide targeted therapy, as all male UTIs are classified as complicated and require culture-directed treatment 3, 2
• Perform renal ultrasound to evaluate for obstruction or structural abnormalities that may be contributing to both UTI and AKI 1
• Calculate baseline creatinine and monitor for AKI progression (≥0.3 mg/dL increase within 48 hours or ≥50% from baseline) 1

Concurrent AKI Management

• Immediately discontinue NSAIDs, hold diuretics and beta-blockers upon AKI diagnosis 1
• Replace fluid losses and consider albumin 1 g/kg/day for 2 days if serum creatinine doubles from baseline 1
• Monitor urine output, vital signs, and volume status closely 1

Empiric Antibiotic Selection

First-Line IV Options (Dose-Adjust for AKI)

• Third-generation cephalosporin (e.g., ceftriaxone or cefotaxime) as monotherapy for systemic symptoms 2
• Amoxicillin plus aminoglycoside or second-generation cephalosporin plus aminoglycoside as alternative combinations 2
• Avoid fluoroquinolones empirically if local resistance rates exceed 10% or if the patient used them within the last 6 months 2

Critical Dosing Considerations in AKI

• Aminoglycosides require extreme caution in AKI due to nephrotoxicity risk, though they achieve excellent urinary concentrations (25-100 fold above plasma levels) 1
• Single-dose aminoglycoside may be considered for simple cystitis only, not for complicated UTI with systemic symptoms 1
• All antibiotics require renal dose adjustment based on creatinine clearance 4

Pathogen-Specific Considerations

If ESBL-Producing Organisms Suspected or Confirmed

• Carbapenems remain the gold standard for ESBL-UTI, though alternatives exist for mild-moderate cases 5, 6
• Meropenem-vaborbactam 4g IV q8h or imipenem-cilastatin-relebactam 1.25g IV q6h are recommended for complicated UTIs caused by carbapenem-resistant Enterobacteriaceae (CRE), with dose adjustment for renal function 1
• Ceftazidime-avibactam 2.5g IV q8h is an alternative for CRE-associated complicated UTIs 1
• Plazomicin 15 mg/kg IV q12h offers lower nephrotoxicity compared to traditional aminoglycosides (16.7% vs 50% acute renal injury in the CARE trial) and may be preferred in AKI patients with CRE 1

Broader Spectrum Pathogens in Males

• Male UTIs have a broader microbial spectrum including E. coli, Proteus, Klebsiella, Pseudomonas, Serratia, and Enterococcus 2
• Antimicrobial resistance is more likely in male UTIs compared to uncomplicated female cystitis 2

Treatment Duration

Standard Approach

• Treat for 14 days when prostatitis cannot be excluded, which is common in male UTIs 2
• Shorten to 7 days if the patient is hemodynamically stable, afebrile for ≥48 hours, and prostatitis is definitively ruled out 2
• Recent evidence suggests 7-day courses may be non-inferior to 14 days in men without complicating conditions, though this remains controversial 2

Transition to Oral Therapy

• Switch to oral antibiotics once clinically stable (afebrile, improving symptoms, tolerating oral intake) 2
• Tailor therapy based on culture and susceptibility results once available 3, 2
• Fluoroquinolones (e.g., levofloxacin 750mg daily for 5 days or 250mg daily for 10 days) are effective oral options if susceptible 4

Special Considerations for AKI Context

Catheter Management

• Remove or change urinary catheter if present, as catheter-associated UTI is a common cause of both infection and AKI 2
• Catheter-associated UTIs account for nearly 80% of hospital-acquired UTIs 7

Monitoring Parameters

• Serial creatinine measurements to assess AKI trajectory and antibiotic dosing needs 1
• Urine output monitoring (target >0.5 mL/kg/h) 1
• Clinical response assessment at 48-72 hours to determine need for antibiotic modification 3

Common Pitfalls to Avoid

• Failing to obtain cultures before antibiotics eliminates the ability to narrow therapy appropriately 3, 2
• Using nephrotoxic aminoglycosides without dose adjustment in established AKI can worsen renal function 1
• Continuing broad-spectrum therapy despite susceptibility results promotes resistance 3
• Undertreating with <7 days duration risks treatment failure in complicated male UTIs 2
• Not investigating for prostatitis, which requires 14-day treatment and is common in male UTIs 2
• Neglecting to address structural abnormalities (obstruction, stones) that perpetuate both UTI and AKI 1, 2
• Continuing diuretics or NSAIDs during AKI management worsens renal outcomes 1